• AI in Drug Development: Promise and Pitfalls

    Bio-IT World | An expert panel of technology and pharmaceutical executives convened at this month's Bio-IT World Venture, Innovation, and Partnering event to discuss the transformative potential of artificial intelligence in drug development—and the significant challenges that still lie ahead. Participants included Rory Kelleher of NVIDIA, Bill Fitzgerald from Google Cloud, Bill Mayo of Bristol-Myers Squibb, Anthony Philippakis of GV (formerly Google Ventures), and Becky Stevenson of HSBC, moderated by Jeremy Goldberg of Arsenal Capital Partners.

    Apr 22, 2025

  • Insilico’s Alex Zhavoronkov Highlights Generative AI's Impact on Drug Discovery and Aging Research

    Bio-IT World | At the Bio-IT World Conference & Expo earlier this month, Alex Zhavoronkov, CEO and founder of Insilico Medicine, shared the company's progress in leveraging generative AI to accelerate drug discovery, particularly focusing on aging research. Celebrating the company's 11th year, Zhavoronkov emphasized his singular mission: helping people live longer, healthier lives.

    Apr 17, 2025

  • AI Continues to Make Strides on Therapeutics and Research Progress

    Bio-IT World | During the final plenary keynote of this year’s Bio-IT World Conference & Expo, we heard from Tris Dyson, Challenge Works, and Jeffrey Rothstein, Johns Hopkins University; Robert Green, Harvard Medical School; and Justin Scheer, Johnson & Johnson Innovative Medicine. They all gave presentations that highlighted artificial intelligence (AI) and machine learning’s (ML) ever-growing roles in research and healthcare, as well as the impact they have on the future of patient treatment, drug development, and more.

    Apr 16, 2025

  • Derek Lowe on AI in Drug Discovery: Between Hype and Hope

    Bio-IT World | At last week’s Venture, Innovation, and Partnering Summit at the Bio-IT World Conference & Expo, Derek Lowe, Director, Chemical Biology & Therapeutics at Novartis BioMedical Research, and John Keilty, venture partner at Third Rock Ventures, sat down for a candid conversation on the pharmaceutical industry and the current state of artificial intelligence and machine learning (AI/ML) in drug discovery.

    Apr 15, 2025

  • Large Language Model Predicts, as Well as Explains, Molecular Properties

    Bio-IT World | Scientists use prior knowledge to solve new problems, and a novel artificial intelligence (AI) system known as LLM4SD (Large Language Model 4 Scientific Discovery) can likewise synthesize knowledge from existing literature. But the method “goes beyond simply repeating information” by interpreting it and coming up with new hypotheses.

    Apr 10, 2025

  • AI Struggles and Opportunities in Life Sciences and Healthcare

    Bio-IT World | At the opening plenary panel at last week’s Bio-IT World Conference & Expo, speakers from pharma, healthcare, and biotech took on the future of AI for pharma and healthcare. Abbie Celniker, Partner, Third Rock Ventures, moderated the conversation which included viewpoints from Per Greisen, President, BioMap; Sofia Guerra, Vice President, Bessemer Venture Partners; Subha Madhavan, Vice President and Head, AI/ML, Quantitative and Digital Sciences, Pfizer; and Sonya Makhni, MD, Medical Director, Mayo Clinic Platform.

    Apr 9, 2025